US and Global Fund Target 3 Million Lenacapavir Beneficiaries for HIV by 2028

The United States and the Global Fund have set a goal to provide lenacapavir, an HIV treatment, to 3 million beneficiaries by 2028. This initiative aims to significantly expand access to critical HIV medication globally.